123 related articles for article (PubMed ID: 25253615)
1. Impact of prior cancer on eligibility for lung cancer clinical trials.
Gerber DE; Laccetti AL; Xuan L; Halm EA; Pruitt SL
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25253615
[TBL] [Abstract][Full Text] [Related]
2. The bottleneck effect in lung cancer clinical trials.
Gonzalez LE; Sutton SK; Pratt C; Gilbertson M; Antonia S; Quinn GP
J Cancer Educ; 2013 Sep; 28(3):488-93. PubMed ID: 23733149
[TBL] [Abstract][Full Text] [Related]
3. Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022.
Xiao H; Vaidya R; Hershman DL; Unger JM
J Clin Oncol; 2024 Jun; 42(16):1953-1960. PubMed ID: 38537158
[TBL] [Abstract][Full Text] [Related]
4. Disparities in older adult accrual to cancer trials: Analysis from the alliance for clinical trials in oncology (A151736).
VanderWalde NA; Dockter T; Wakefield DV; Satele D; Sloan J; Jagsi R; Lichtman SM; Freedman RA; Lafky JM; Muss H; Cohen HJ; Le-Rademacher J; Jatoi A
J Geriatr Oncol; 2022 Jan; 13(1):20-26. PubMed ID: 34364834
[TBL] [Abstract][Full Text] [Related]
5. Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).
Vaidya R; Unger JM; Qian L; Minichiello K; Herbst RS; Gandara DR; Neal JW; Leal TA; Patel JD; Dragnev KH; Waqar SN; Edelman MJ; Sigal EV; Adam SJ; Malik S; Blanke CD; LeBlanc ML; Kelly K; Gray JE; Redman MW
JCO Precis Oncol; 2023 Sep; 7():e2300218. PubMed ID: 37677122
[TBL] [Abstract][Full Text] [Related]
6. Shrinking sample sizes in lung cancer trials: Various explanations, open questions.
Olivier T; Addeo A
Eur J Cancer; 2024 Mar; 199():113527. PubMed ID: 38237374
[No Abstract] [Full Text] [Related]
7. Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer.
Pruitt SL; Laccetti AL; Xuan L; Halm EA; Gerber DE
Br J Cancer; 2017 Mar; 116(6):717-725. PubMed ID: 28196065
[TBL] [Abstract][Full Text] [Related]
8. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.
Laccetti AL; Pruitt SL; Xuan L; Halm EA; Gerber DE
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25667420
[TBL] [Abstract][Full Text] [Related]
9. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.
Kim ES; Bruinooge SS; Roberts S; Ison G; Lin NU; Gore L; Uldrick TS; Lichtman SM; Roach N; Beaver JA; Sridhara R; Hesketh PJ; Denicoff AM; Garrett-Mayer E; Rubin E; Multani P; Prowell TM; Schenkel C; Kozak M; Allen J; Sigal E; Schilsky RL
J Clin Oncol; 2017 Nov; 35(33):3737-3744. PubMed ID: 28968170
[TBL] [Abstract][Full Text] [Related]
10. Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.
Garcia S; Bisen A; Yan J; Xie XJ; Ramalingam S; Schiller JH; Johnson DH; Gerber DE
J Thorac Oncol; 2017 Oct; 12(10):1489-1495. PubMed ID: 28802905
[TBL] [Abstract][Full Text] [Related]
11. Impact of prior cancer history on the overall survival of younger patients with lung cancer.
Liu J; Zhou H; Zhang Y; Fang W; Yang Y; Hong S; Chen G; Zhao S; Chen X; Zhang Z; Xian W; Shen J; Huang Y; Zhao H; Zhang L
ESMO Open; 2020 Feb; 5(1):. PubMed ID: 32054633
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer: An Initial Report From the Surveillance, Epidemiology, and End Results Program.
Murphy CC; Gerber DE; Pruitt SL
JAMA Oncol; 2018 Jun; 4(6):832-836. PubMed ID: 29167866
[TBL] [Abstract][Full Text] [Related]
13. Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis.
Laccetti AL; Pruitt SL; Xuan L; Halm EA; Gerber DE
Lung Cancer; 2016 Aug; 98():106-113. PubMed ID: 27393515
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a prediction model for all-cause mortality in maintenance dialysis patients: a multicenter retrospective cohort study.
Wu J; Li X; Zhang H; Lin L; Li M; Chen G; Wang C
Ren Fail; 2024 Dec; 46(1):2322039. PubMed ID: 38415296
[TBL] [Abstract][Full Text] [Related]
15. Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses.
Zhang J; Lin R; Chen X; Yan F
Clin Trials; 2024 Jun; 21(3):308-321. PubMed ID: 38243401
[TBL] [Abstract][Full Text] [Related]
16. Racial and Ethnic Disparities in Survival Among People With Second Primary Cancer in the US.
Sung H; Nisotel L; Sedeta E; Islami F; Jemal A
JAMA Netw Open; 2023 Aug; 6(8):e2327429. PubMed ID: 37540510
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of the presence or absence of prior cancer in patients with cancer using cure models: A population-based study.
Kudo H; Morishima T; Fujii M; Nagayasu M; Ma C; Sobue T; Ohno Y; Miyashiro I
Cancer Sci; 2023 Oct; 114(10):4041-4051. PubMed ID: 37387361
[TBL] [Abstract][Full Text] [Related]
18. Revisiting Exclusion of Prior Cancer in Clinical Trials of Male Breast Cancer.
Rathod A; Murphy CC; Rahimi A; Pruitt SL
J Cancer; 2023; 14(5):737-740. PubMed ID: 37056393
[No Abstract] [Full Text] [Related]
19. Survival in non-small cell lung cancer patients with versus without prior cancer.
Sato A; Morishima T; Takeuchi M; Nakata K; Kawakami K; Miyashiro I
Sci Rep; 2023 Mar; 13(1):4269. PubMed ID: 36922574
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
